| (Values in U.S. Thousands) | Oct, 2024 | Jul, 2024 | Apr, 2024 | Jan, 2024 | Oct, 2023 |
| Sales | 8,403,000 | 7,915,000 | 8,589,000 | 8,089,000 | 7,984,000 |
| Sales Growth | +6.17% | -7.85% | +6.18% | +1.32% | +3.66% |
| Net Income | 1,269,000 | 1,043,000 | 643,000 | 1,322,000 | 909,000 |
| Net Income Growth | +21.67% | +62.21% | -51.36% | +45.43% | +13.20% |
Medtronic Inc (MDT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Medtronic, Inc. acquired Ireland-based Covidien plc. The acquisition resulted in the formation of a new holding company incorporated in Ireland - Medtronic plc. The company currently generates revenues from four major segments - namely Cardiovascular Portfolio, Medical Surgical Portfolio, Neuroscience Portfolio and Diabetes. The Cardiovascular Portfolio, formerly reported as the Cardiac and Vascular Group, includes the Cardiac Rhythm & Heart Failure, Structural Heart & Aortic and Coronary & Peripheral Vascular divisions. The Medical Surgical Portfolio, formerly reported as the Minimally Invasive Therapies Group, includes the Surgical Innovations and the Respiratory, Gastrointestinal & Renal divisions. Neuroscience consists of Cranial & Spinal Technologies, Specialty The Neuroscience Portfolio, formerly reported as the Restorative Therapies Group, includes the Cranial & Spinal Technologies, Specialty Therapies, and Neuromodulation divisions.
Fiscal Year End Date: 04/30